STOCK TITAN

NuSkin Enterprises (NUS) DEF 14A Filings

NUS NYSE

Here are the DEF 14A proxy statements from NuSkin Enterprises, Inc. (NUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUS filings page.

Rhea-AI Summary

Nu Skin Enterprises is asking stockholders to vote at its May 28, 2026 annual meeting on four items: electing nine directors, an advisory vote on executive pay, approving an amended and restated 2024 Omnibus Incentive Plan, and ratifying PricewaterhouseCoopers LLP as auditor for 2026.

The company highlights strong governance practices, including a mostly independent board, separate Chair and CEO roles, a lead independent director, annual board/committee evaluations, and robust risk, cybersecurity and sustainability oversight. Executive pay is heavily performance-based: 2025 cash incentives paid at 21.9% of target after financial metrics came in below minimum levels, while some performance stock units paid out partly or not at all.

In 2025, Nu Skin generated $1.49 billion in revenue with core Nu Skin gross margin of 77.4%, and completed a $250 million sale of its Mavely business, using proceeds to reduce debt and fund innovation. CEO Ryan Napierski’s 2025 compensation was $5.97 million, largely in equity, and 97% of votes supported the prior say-on-pay proposal, which the board views as endorsement of its pay-for-performance design.